See more : US Copper Corp. (USCUF) Income Statement Analysis – Financial Results
Complete financial analysis of Decibel Therapeutics, Inc. (DBTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Decibel Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Okamura Corporation (7994.T) Income Statement Analysis – Financial Results
- Quixant Plc (QXT.L) Income Statement Analysis – Financial Results
- Bubs Australia Limited (BUB.AX) Income Statement Analysis – Financial Results
- Enterprise Diversified, Inc. (SYTE) Income Statement Analysis – Financial Results
- Greenlight Capital Re, Ltd. (GLRE) Income Statement Analysis – Financial Results
Decibel Therapeutics, Inc. (DBTX)
About Decibel Therapeutics, Inc.
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 40.33M | 29.85M | 25.32M | 29.41M | 26.17M |
| General & Administrative | 23.63M | 20.38M | 14.24M | 14.68M | 11.69M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.63M | 20.38M | 14.24M | 14.68M | 11.69M |
| Other Expenses | 0.00 | 12.00K | 171.00K | 0.00 | 0.00 |
| Operating Expenses | 63.96M | 50.23M | 39.56M | 44.08M | 37.86M |
| Cost & Expenses | 63.96M | 50.23M | 39.56M | 44.08M | 37.86M |
| Interest Income | 1.19M | 193.00K | 55.00K | 1.41M | 1.70M |
| Interest Expense | 1.19M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.46M | 1.41M | 1.64M | 1.77M | 1.47M |
| EBITDA | -62.50M | -48.82M | -39.56M | -42.31M | -36.39M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -63.96M | -50.23M | -39.56M | -44.08M | -37.86M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.19M | 205.00K | 226.00K | 1.41M | 1.70M |
| Income Before Tax | -62.77M | -50.03M | -39.34M | -42.67M | -36.16M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 240.00K | 1.80M | -1.70M | -1.41M | 1.70M |
| Net Income | -63.01M | -51.82M | -37.64M | -41.26M | -36.16M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.52 | -2.38 | -1.63 | -5.61 | -4.98 |
| EPS Diluted | -2.52 | -2.38 | -1.63 | -5.61 | -4.98 |
| Weighted Avg Shares Out | 24.96M | 21.73M | 23.12M | 7.36M | 7.26M |
| Weighted Avg Shares Out (Dil) | 24.96M | 21.73M | 23.12M | 7.36M | 7.26M |
Decibel Therapeutics' CVR Appears Around Fair Value
DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTX
DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTX
Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update
Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals
Shareholder Alert: Ademi LLP investigates whether Decibel Therapeutics, Inc. has obtained a Fair Price in its transaction with Regeneron
DBTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Decibel Therapeutics, Inc. Is Fair to Shareholders
Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal
Decibel Therapeutics shoots up 72% on Regeneron bid
Regeneron buying small cap Decibel Therapeutics for $4 a share
Source: https://incomestatements.info
Category: Stock Reports